ArriVent BioPharma (AVBP) Net Equity Issued and Repurchased (2023 - 2026)

ArriVent BioPharma (AVBP) has 4 years of Net Equity Issued and Repurchased data on file, last reported at $54.7 million in Q1 2026.

• For the quarter ending Q1 2026, Net Equity Issued and Repurchased rose 739.84% year-over-year to $54.7 million; the trailing twelve-month figure through Mar 2026 stood at $95.9 million (down 50.09% YoY), and the FY2025 full-year result was $202.6 million, up 8.97% from the prior year.
• Net Equity Issued and Repurchased improved to $54.7 million in Q1 2026, from $34.7 million in the prior quarter.
• In the past five years, Net Equity Issued and Repurchased ranged from a high of $185.6 million in Q1 2024 to a low of -$24000.0 in Q2 2023.
• A 4-year average of $54.4 million and a median of $39.8 million in 2023 frame the typical range for Net Equity Issued and Repurchased.
• Across the five-year window, Net Equity Issued and Repurchased slumped 96.49% in 2025 and surged 739.84% in 2026, its largest moves.
• Tracing AVBP's Net Equity Issued and Repurchased over 4 years: stood at -$24000.0 in 2023, then surged by 773562.5% to $185.6 million in 2024, then sank by 81.33% to $34.7 million in 2025, then surged by 57.9% to $54.7 million in 2026.
• Business Quant data shows AVBP's Net Equity Issued and Repurchased at $54.7 million in Q1 2026, $34.7 million in Q4 2025, and $6.5 million in Q1 2025.